At the population level, the humoral response to SARS-CoV-2 is heterogenous. As such, the traditional antibody assay using eithe r the spike or nucleocaspid as antigens are less sensitive. Additionally, the accumulation of SARS-CoV-2 mutations will further reduce the performance of existing assays. To overcome this challenge, EpitoGen Technology, has been developed to produce a set of unique, highly sensitive COVID-19 ELISA tests.
EpitoGen Technology efficiently expresses short epitopes to vastly improve antibody tests. The epitope antigen (EpitoGen) is fused in the middle of an inert scaffold protein and displayed on the top of the scaffold ideally suited for a number of antigen/antibody-based assays such as ELISA and lateral flow.
The EpitoGen Universal COVID-19 ELISA Test was designed for maximum sensitivity and specificity. The antigen consists of a set of 15 immunodominant epitopes from N, S, M, ORF3a and ORF7a viral proteins, and their corresponding major circulating mutants (79 prevalent mutations). The combinations of the epitogens in the assay offers the ability to detect the broadest range of human anti-COVID-19 antibodies.
Linear and conformational immunodominant epitopes are used to enrich the positive signal. High specificity is achieved as cross-reactive epitopes are eliminated.
This EpitoGen Test includes the IgG ELISA plate and dilution buffer. Other materials are to be supplied by the user.
Discounts are available for bulk quantities. Inquire for pricing.
Please note: This product is for research use only.